Table A2.
Baseline characteristics of AKI progression.
| Characteristics | No AKI Progression (n = 185 (78.7%)) |
AKI Progression (n = 52 (21.3%)) | p-Value |
|---|---|---|---|
| Age (years) | 63 (55, 71) | 65 (50, 70) | 0.785 |
| Gender (% female) | 64 (34.6) | 25 (50.0) | 0.068 |
| BMI (kg/m2) baseline creatinine (µmol/L) |
22.4 (20.6, 24.9) 79 (69, 95) |
23.7 (20.7, 26.9) 92 (70, 101) |
0.086 0.113 |
| Comorbidities | |||
| CKD (%) | 10 (5.4) | 3 (6.0) | 1.000 |
| CVD (%) | 20 (10.9) | 9 (18.0) | 0.271 |
| DM (%) | 33 (17.8) | 11 (22.0) | 0.642 |
| Malignancy (%) | 16 (8.7) | 3 (6.0) | 0.736 |
| Operation (%) | 121 (65.4) | 33 (66.0) | 1.000 |
| Infection * (%) | 34 (18.4) | 13 (26.0) | 0.319 |
| Sepsis (%) | 28 (19.2) | 13 (26.0) | 0.384 |
| SIRS | 2 (1,3) | 3 (2, 3) | 0.565 |
| SOFA | 6 (2,7) | 7 (5, 9) | 0.001 |
| qSOFA | 0 (0,1) | 1 (0, 0) | 0.142 |
| Mechanical ventilation (%) | 127 (6.0) | 46 (92.0) | 0.002 |
| Vital parameters | |||
| Heart rate (bpm) | 80 (70,92) | 95 (80, 104) | 0.001 |
| MAP (mmHg) | 85.0 (73.3, 98.0) | 79.8 (69.1, 93.4) | 0.143 |
| Respiratory rate (resp/min) | 16.0 (14.0, 23.0) | 20.0 (16,0 25.0) | 0.114 |
| Body temperature (°C) | 36.1 (35.4, 37.2) | 37.1 (35.4, 37.4) | 0.630 |
| Laboratory values | |||
| CRP (mg/L) | 6.90 (2.05, 37.00) | 9.65 (6.45, 70.80) | 0.018 |
| Leucocytes(10^9/L) | 12.5 (9.3, 16.3) | 13.1 (10.8, 17.9) | 0.274 |
| Thrombocytes (10^9/L) | 188 (150, 242) | 185 (127, 253) | 0.801 |
| Bilirubin (umol/L) | 9 (6, 14) | 12 (8, 19) | 0.038 |
| Albumin (g/L) | 30 (25, 34) | 28 (24, 33) | 0.084 |
| Creatinine (µmol/L) | 72 (59, 88) | 91 (72, 121) | 0.001 |
| Calprotectin (μg/mL) | 4.33 (2.45, 6.62) | 4.60 (2.64, 8.08) | 0.300 |
| Thiols (µmol/L) | 256.24 (162.72, 359.70) | 230.49 (116.14, 326.12) | 0.073 |
| APACHE II | 15 (11, 20) | 17 (13, 21) | 0.058 |
| APACHE IV | 46 (34, 66) | 60 (46, 91) | <0.001 |
| <7-day Mortality (%) | 8 (4.3) | 4 (8.0) | 0.493 |
| <28-day Mortality (%) | 18 (9.7) | 7 (14.0) | 0.542 |
Data are presented as median (IQR) of proportions. p-values were calculated using a two-tailed Mann Whitney U test or chi-square test, while significant differences are indicated in bold. * Infection is a confirmed infection. AKI progression is defined as a change in the KDIGO stage within 48 h after ICU admission. The highest KDIGO stage in 48 h is used. CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment score; qSOFA, quick SOFA; CPR, cardiopulmonary resuscitation; MAP, mean arterial pressure; CRP, C-reactive protein; and APACHE, Acute Physiology And Chronic Health Evaluation.